EXPRESS SCRIPTS*

Express Communications

9/1/2022

Medicare Part D Formulary Change

The product changes noted below will be implemented on the Medicare Part D Plan:

New Added Products: Effective 9/1/2022

| Drug | Reason | Cost sharing** | Restrictions*** |
|---|----------|----------------|-----------------|
| bexarotene 1 % topical gel | New Drug | Tier 5 | PA |
| fesoterodine er 4 mg tablet,extended release 24 hr | New Drug | Tier 3 | |
| fesoterodine er 8 mg tablet,extended release 24 hr | New Drug | Tier 3 | |
| sorafenib 200 mg tablet | New Drug | Tier 5 | PA QL |
| vilazodone 10 mg tablet | New Drug | Tier 3 | QL |
| vilazodone 20 mg tablet | New Drug | Tier 3 | QL |
| vilazodone 40 mg tablet | New Drug | Tier 3 | QL |

Future Removed Products: There were no future removed products this month.

Cost Sharing Tier Changes: There were no cost sharing tier changes this month.

Mutual of Omaha Rx Plus: 22018

^{*}Consult your Medical provider for changes or recommendations to your medical care and prescription therapy

**Please consult the plan benefit design for copay/coinsurance amounts

^{***}Indicates a restriction of Step Therapy, Prior Authorization or Quantity Limits may exist [LA] = Limited Access, [PA] = Prior Authorization, [QL] = Quantity Limit, [ST] = Step Therapy